Over 1.8 million nonprofits and charities for donors, volunteers and funders

Claim This Nonprofit

More Info

Add to Favorites

Share this Nonprofit

Donate

Nonprofit Overview

Causes: Government & Public Administration, Health, Medical Research, Mental Health, Mental Health Treatment

Mission: Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS furthers its mission by: -Developing psychedelics and marijuana into prescription medicines -Training therapists and working to establish a network of treatment centers -Supporting scientific research into spirituality, creativity, and neuroscience -Educating the public honestly about the risks and benefits of psychedelics and marijuana MAPS envisions a world where psychedelics and marijuana are safely and legally available for beneficial uses, and where research is governed by rigorous scientific evaluation of their risks and benefits.

Results: MAPS has completed two Phase 2 FDA studies using MDMA-assisted psychotherapy to treat PTSD, and is in the process of four other similar studies. MAPS also has a study looking at LSD-assisted psychotherapy for treating end-of-life anxiety, an outcome study of the benefits of ibogaine for opiate dependence, and a protocol to investigate medical marijuana to relieve symptoms of PTSD.

Target demographics: Any person whose life may be aided by the transformative nature of psychedelic psychotherapy

Geographic areas served: Worldwide

Programs: Maps' primary focus is research into mdma-assisted psychotherapy ($1,094,575), especially phase 2 research into mdma-assisted psychotherapy in subjects with chronic, treatment-resistant ptsd. In this fiscal year, maps treated the 18th subject in our charleston, south carolina mdma/ptsd study in 24 veterans, firefighters and police officers. An 8th subject was treated in our study in boulder, colorado for people suffering from ptsd from any source, a fourth subject was treated in our mdma/ptsd study in beer yaakov, israel, and an irb approved the amendments for our mdma/ptsd study in vancouver, canada. A 7th therapist participated in our mdma-assisted psychotherapy therapist training study. In addition to our core clinical research, this fiscal year we began planning a series of studies in collaboration with researchers who work with the u. S. Department of veterans affairs' national center for ptsd. We'll be exploring the use of mdma along with more traditional psychotherapeutic methods for treating ptsd including cognitive-behavioral conjoint therapy, cognitive processing therapy, and prolonged exposure therapy. We also began our study looking at the safety and efficacy of using mdma-assisted therapy for anxiety in adults on the autism spectrum and began preparations for a study of mdma-assisted psychotherapy for end-of-life anxiety. These studies will grow significantly in the coming year. Mdma-study related program expenses include costs of video data storage and streaming systems development, budgeting, contracting, and meetings; the costs of developing the treatment manual; training therapists; blinded therapist adherence training; and costs of reviewing and documenting all published mdma literature. There are also mdma-study related supervision of therapists, presentation of our data at professional conferences, and costs to manage the mdma purchased early in our work and to secure the drug for phase 3 trials expected to begin in 2016. Clinical research general costs cover the development of the infrastructure needed for our mdma clinical trials, including work with communications and fundraising departments, staff professional development and conferences, and video streaming and statistical software. Most of the clinical research expenses are personnel, including personnel at each study site: principal investigators, co-investigators, independent raters, overnight physicians, attendant, and study coordinators, as well as maps' internal staff: the clinical director, research associates, information specials, data coordinators and statistical consultants. Ibogaine research expenses were dedicated to completing our studies in mexico ($3,816), and new zealand ($6,329). Lsd research expenses ($12,185) were primarily used for the march 2014 publication of our lsd end-of-life anxiety article in the journal of nervous and mental disease. Marijuana research ($14,905) covered the costs of developing the protocol for a pilot study in which marijuana will be tested to manage symptoms in 76 veterans with chronic, treatment-resistant ptsd, and our efforts to end the public health service (phs) review and the national institute of drug abuse (nida) monopoly of the sale of marijuana for clinical research.

education expenses include harm reduction, events, publications and communications programs. Our zendo project provides a supportive space for people undergoing difficult psychedelic experiences in order to help turn those experiences into opportunities for learning and personal growth, and to reduce the number of drug-related psychiatric hospitalizations and arrests. Services were provided at five major events in fiscal year 2014: burning man (black rock city, nv), envision (costa rica), afrikaburn (south africa), bicycle day (san francisco, ca), and lightning in a bottle (bradley, ca). In order to share recent findings and to inspire existing and new support, maps produced events on psychedelic and marijuana research in colorado, vancouver and santa cruz; and attended more than 17 events that others produced, providing speakers, exhibits, sales of books and maps bulletins, and free distribution of clinical protocols and articles from peer-reviewed journals. Communications included publishing three maps bulletins, and 12 email newsletters, maintaining maps. Org, mdmaptsd. Org, mapscanada. Org, psychedelicscience. Org, and launching mdma-autism. Org. Maps produced "manifesting minds," with north atlantic books, reprinted albert hofmann's "lsd: my problem child," and began work with stanislav grof on his new book, "the visionary world of h. R. Giger. " in spring 2014, maps offered its first webinar, "psychedelic science," in collaboration with evolver learning labs. Maps saw significant growth in coverage of its work in social, online, and traditional media. Maps. Org had 511,449 unique visits and 1,809,246 page views. Facebook likes more than doubled to 89,282. Twitter followers increased 140%, to 17,099. Youtube subscriptions increased 256% to 5,313. Maps received 344 unique media mentions from online and print publications with significant reach. Media outlets include the los angeles times, the new york times, the san francisco chronicle, reason, scientific american, cnn, usa today, msnbc, time, associated press, fox news, forbes, nbc news, playboy, santa cruz sentinel, tricycle, business insider, npr, vice, and southern california public radio (kpcc).

this year, maps operationalized its long-running fiscal sponsorship program, clarifying and updating contracts, process, and structure. This program supports projects that are in alignment with maps mission and vision by offering donors a way to give to a 501(c) 3 nonprofit organization. Maps monitors the project budget, takes a small fee, and sends the donor a receipt for their contribution.

Community Stories

285 Stories from Volunteers, Donors & Supporters

1

General Member of the Public

Rating: 5

I have personally experienced the transformative effects of psychedelic tools like LSD and psilocybin, and am convinced that they will revolutionize the field of psychotherapy. We need to do more research on these substances, to better our understanding of how we can use them in healing and therapeutic settings. That is why I support MAPS.

General Member of the Public

Rating: 5

Psychedelics have incredible potential in mental health treatment, and it is an outrage and a travesty the way they have been demonized for the past several decades. MAPS is doing great work in driving forward the research and study of psychedelics.

Marcelo T.

General Member of the Public

Rating: 5

MAPS helps the world to make the best out of a practical, chemical, historical and public health information that has been out for a long time but not put in the knowledge of the general public.

General Member of the Public

Rating: 5

MAPS is doing amazing work. I believe that psychedelics, including marajuana, are going to be the new frontier of medication.

2 Pate B.

General Member of the Public

Rating: 5

MAPS brings reason and scientific insight to the table when discussing psychedelics. Where drug policy has been bound by propaganda, MAPS seeks to expose the truth; psychedelics are medicine, and warrant extensive research.

2 Steve152

General Member of the Public

Rating: 5

For nearly 30 years, this valiant organization has been spearheading efforts to legitimize efficacious, safe, and considerably inexpensive solutions to a panoply of mental health issues. Their accomplishments are astounding, and such immense success is especially admirable when one considers the sustained and onerous adversities they have had to push against to press forward.

And yet they make it look easy, with smiles and optimism always in abundance. Thanks to Rick Doblin and his organization, psychedelic research has reached a new zenith in an era when it is needed more than ever.




1

General Member of the Public

Rating: 5

The important research being done by MAPS is a personal one. As anyone who suffers from a chronic illness knows, dealing with the symptoms while trying to live our lives, isn't easy. Not only has marijuana treated the majority of my symptoms , mostly physical, but psychedelics have treated my mental health that comes along with a chronic illness.

1

General Member of the Public

Rating: 5

People are going to use mind altering drugs NO MATTER WHAT! Research and education is the only way to prevent the misuse of these substances. Ignorance of proper drug use is the most damage a drug can do to society. MAPS is hope for a better future!

1 Aeolian H.

General Member of the Public

Rating: 5

MAPS is doing research that will allow people in the modern Western world to finally understand that consciousness can be changed, trauma can be healed, and neurosis can be transmuted into strength. MAPS is changing medical views of what is pathological/ terminal and what is within our power to transform. Though this work could have been accomplished long ago if not for draconian drug laws, MAPS should be commended a thousand times more profusely since they have managed to thrive even within a resistant and ignorant cultural paradigm. This is history that will be remembered fondly by anyone who enjoys the benefits of exploring the freedom of human consciousness in the future. In my personal opinion, the victory of this research will change the world in ways that will be analogous to any of the great philosophical triumphs in history. I recommend that MAPS be awarded with the highest honors imaginable since their main purpose is to deeply study human consciousness and use that knowledge to alleviate as much suffering as they can without compromising health, quality of life, or individual liberty.

2 Jennifer416

General Member of the Public

Rating: 5

The insights gained by these plant medicines can be tremendously healing and life-changing. This is the most important research being done today to further our understanding of the effect of plant medicines on our mental health. This could be the most effective aid for ending depression, ptsd, anxiety, addiction, and fear of death anxiety in hospice situations. I am so thankful this research is being pursued. I think the benefits to humanity in terms of limiting suffering will be tremendous.